• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

    5/15/26 2:09:52 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world's largest pre-college STEM competition.

    TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Society for Science (the Society) announced that Hikaru Kuribayashi, 17, of Sapporo, Japan won the $100,000 George D. Yancopoulos Innovator Award at the Regeneron International Science and Engineering Fair 2026 (Regeneron ISEF), the world's largest precollege science and engineering competition.

    Key Takeaways:

    • This year's finalists received more than $7 million in awards based on their projects' creativity, innovation, and depth of scientific inquiry.
    • The top winners were honored at the Phoenix Convention Center in Phoenix, Arizona during two award ceremonies: the Special Awards Ceremony on May 14, and the Grand Awards Ceremony on May 15.
    • Top prizes ranged from $10,000 to $100,000 and were awarded to support students' education and continued research, investing in the next generation of scientific leaders.
    • The competition featured more than 1,700 young STEM students, representing more than 67 countries, regions, and territories.
    • Hikaru Kuribayashi, 17, of Sapporo, Japan won first place and received the $100,000 George D. Yancopoulos Innovator Award for his creation of a simulation program to understand complex folding, like in origami. The award is named in honor of George D. Yancopoulos, the pioneering drug researcher and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer.
    • Lakshmi Agrawal, 18, of Bellevue, Washington, and Nikola Veselinov, 17, of Sofia, Bulgaria each received the Regeneron Young Scientist Awards of $75,000, Agrawal for a sponge that removes salmon-killing pollutants from water, and Veselinov for describing a new theorem in mathematics that describes the conditions under which certain equations cannot be solved using basic math functions.
    • Other top prizes went to projects in Environmental Engineering, Technology Enhances the Arts, and Materials Science.



    "Congratulations to the winners of this year's Regeneron International Science and Engineering Fair," said Maya Ajmera, President and CEO of Society for Science and Executive Publisher of Science News. "These students never fail to inspire me. They come from different backgrounds, different disciplines, and different corners of the world, and they are taking on some of our most urgent challenges with rigor, imagination, and determination. At a moment when bold thinking is needed most, they are proof of what's possible. I couldn't be more optimistic about the future."

    Regeneron ISEF brings together the world's most promising young scientists and engineers to showcase research with real-world impact. Through this competition, Regeneron and the Society are fostering the next generation of STEM leaders who are helping to solve real-world challenges to improve our world.

    "Congratulations to the extraordinary young scientists of Regeneron ISEF 2026. My own scientific journey began in high school, supported by great teachers, driven by a fearless youthful belief that I could cure my grandmother's disease, and inspired by the excitement and challenge of science competitions," said George D. Yancopoulos, M.D., Ph.D., co-Founder, co-Chairman, President and Chief Scientific Officer of Regeneron. "I continue to believe that the best hope for overcoming the greatest threats facing humanity lies in inspiring brilliant young minds to take on these challenges. That's why Regeneron proudly invests hundreds of millions of dollars in programs like ISEF and the Science Talent Search. We're celebrating not only what these students have already achieved, but the extraordinary impact we know they'll have next."

    • Hikaru Kuribayashi, 17, of Sapporo, Japan, won first place and received the George D. Yancopoulos Innovator Award of $100,000 for his work to predict how materials can fold in complex ways. He created a simulation program to understand complex folding, like in origami. Current methods for predicting folding can either only trace one path at a time or fail to test all the possibilities. Hikaru's simulation software uses a statistical method called Markov Chain Monte Carlo. This method samples many possible scenarios and uses those patterns to estimate the most probable answers. It allows the simulation to examine all possibilities at once in a single run. Hikaru's software predicted known solutions, such as the folding of a ladybug wing. This program could help design devices that need to be packed into small spaces and unfolded later, such as solar sails for satellites, medical devices or emergency pop-up shelters.
    • Lakshmi Agrawal, 18, of Bellevue, Washington, received the Regeneron Young Scientist Award of $75,000 for a sponge that removes salmon-killing pollutants from water. When adult coho salmon spawn, they return to the urban streams of Washington's Puget Sound region. In some streams, up to 80% of these fish die before spawning. These streams are polluted with a chemical from tires called 6PPD-quinone. Previous work found that 6PPD-quinone was a primary cause of these salmon deaths. To remove the pollutant from water, Lakshmi created sponge-like filters from jute plant waste. In laboratory tests of water with tire particles, she showed the filters removed up to 80% of the pollutant. It can also remove other heavy metals and particles. It also naturally breaks down in the environment. Compared with current alternatives, Lakshmi's solution required 85% less energy to produce and reduced costs by about 98%. Her work may lead to a scalable way to protect aquatic ecosystems and drinking water from tire-related contaminants.
    • Nikola Veselinov, 17, of Sofia, Bulgaria, received the Regeneron Young Scientist Award of $75,000 for describing a new theorem in mathematics. Mathematicians have found that equations that follow f(x) = a can be solved with basic math functions, except in a few specific cases. Nikola analyzed those isolated cases of unsolvability to find a common thread. He combined several advanced mathematical concepts. He combined ideas from topology, symmetry and Galois theory. He used these approaches to analyze when equations become impossible to solve exactly. By doing this, he described the conditions under which the equation f(x) = a cannot be solved using basic math functions. His work may impact equations used in physics and in describing how objects move through space. 



    Other Regeneron ISEF top honors include:

    • Evan Budz, 15, of Ontario, Canada, received the Gordon E. Moore Award for Positive Outcomes for Future Generations of $50,000 for making an AI-powered imaging robot to find and measure tiny pieces of plastic in water. Microplastics threaten animals and aquatic ecosystems worldwide. Current ways to measure microplastics are costly and hard to implement. To create a faster and more practical solution, Evan designed and built an underwater 3D holographic camera. The camera is mounted on a self-propelled robot that swims through the water like a sea turtle. He also trained AI models to find pieces of plastic smaller than a red blood cell in the underwater images. His models were 94% accurate at telling microplastics apart from other particles. He tested it in 10 bodies of water, scanning more than 80,000 3D images for plastic particles and microorganisms. His work could make it easier and faster to monitor water sources for microplastics.
    • Anusha Arora, 15, of Bellevue, Washington, received the F. Thomson Leighton and Bonnie Berger Family Prize for STEM Excellence of $50,000 for her music therapy device. Although music therapy is a recognized approach for supporting mental health, access is limited. Cost, provider shortages and lack of insurance coverage make music therapy inaccessible. To combat this, Anusha created a portable music therapy device. Her platform delivers tailored, adaptive music based on input from finger sensors. The platform combines 11 AI programs to detect emotions and generate music in real time. Across several experiments, people using the device showed reductions in stress and anxiety. Users also stayed more engaged with the therapy sessions. The platform could make it easier for people to access music therapy, which can help reduce stress, anxiety and depression.
    • Kevin Sun, 17, of Andover, Massachusetts, received the Craig R. Barrett Award for Innovation of $10,000 for developing a new way to sort plastic recyclables using a dissolvable tag. One of the major challenges with plastic recycling is inaccurate sorting of the different plastic types. Colored plastic can also be hard to sort for proper recycling. To improve sorting accuracy, Kevin printed a radio frequency tag on plastic materials. These materials are similar to those used in plastic manufacturing. The tag acts like a wireless barcode, identifying the plastic type for sorting purposes. He made the tag from a conductive material called MXene that can transmit radio frequency signals. The tag is covered by a thin protective coating that dissolves in alkaline water. Experiments showed that both materials quickly break down during the hot washing step already used in recycling plants. Because they wash away, the plastic can be recycled without contamination. Kevin's experiments showed the printed tag remained readable for at least six weeks. This practical approach offers a potential way to improve plastic recycling.
    • Illaria Liedtke, 17, of Rye, New York, received the H. Robert Horvitz Prize for Fundamental Research of $10,000 for studying brain cells using magnets. Nervous system diseases can disrupt calcium signaling in brain cells called astrocytes. Researchers increasingly believe astrocytes play an important role in brain disease, but there are few ways to precisely control them remotely. Inspired by the physics of magnetic levitation, Illaria trialed a way to use magnets to modify signals sent from astrocyte cells. To do this, she first created a material that responds to magnetic fields. In the lab, she added the material to astrocyte cells. When she exposed the cells to magnets, their calcium signaling, which the cells use to communicate, changed. Different magnetic conditions made different patterns. Illaria also studied the biology of the system. She confirmed that a channel in the astrocytes called TRPV4 was responsible for the changes in calcium signaling. Under conditions that mimic a brain injury, she was able to use the system to reduce signs of cellular stress. Her research could help lead to new therapies that regulate brain activity without implanted electrical devices.
    • Aakash Manaswi, 17, of Orlando, Florida, received the Peggy Scripps Award for Science Communication of $10,000 for creating a carbon dioxide (CO2)-based system that kills honey bee pests. Honey bees are important pollinators that support many global food crops, but up to half of all colonies die off each year. A common pest is the varroa mite. Current treatments for these mites leave chemical residues in honey and beeswax and can harm bees. Aakash's earlier work showed that CO2 is an effective way to control the mites while minimizing harm to the bees. For this year's project, he tested the long-term safety and real-world performance of his "Mite Blower" CO2 treatment prototype. His system was as good or better at getting rid of the mites as existing pesticides. It also avoided many of their harmful side effects. In a 10-week field trial of 60 hives, the CO2-treated bees were healthier and made more honey than hives treated with pesticides. Aakash's Mite Blower may be a cheaper and safer alternative to treating varroa mite infestations, potentially reducing the loss of hives.
    • Evan Morris, 18, of Saint Paul, Minnesota, received the Mary Sue Coleman Award for Life Science Innovation & Impact of $10,000 for his low-cost system to detect and interrupt seizure-like behavior in a worm model. Some people with epilepsy get brain stimulation to help control seizures. Finding the right stimulation settings often takes months of trial and error. This can be expensive and frustrating for patients. To study brain stimulation methods, Evan used gene editing to add an ultrasound-sensitive channel into the brain cells of a worm. He then built a computer controller to detect seizure-like activity. When it detected a seizure, the program would trigger an ultrasound to activate the channel and stop the behavior. Using the system, Evan tested different stimulation settings to find which reduced seizures the most. He reduced seizure recurrence by 70.1% and lowered overall seizure activity by nearly 30%. His work may lead to faster, lower-cost ways to study brain stimulation in living systems. 
    • Benedikt Kienle, 19, of Lancaster, Pennsylvania, and Filip Lajciak, 18, of Dubnica nad Vahom, Slovakia, received the Dudley R. Herschbach SIYSS Award.
    • Moitri Santra, 17, of Oviedo, Florida, along with Bennett Huang, 17, and Jason Pan, 17, of Mclean, Virginia, received the EU Contest for Young Scientists Award. Their projects will represent Regeneron ISEF at the EU Contest for Young Scientists to be held this September in Kiel, Germany.



    In addition to the Top Award winners, more than 540 projects received awards and prizes for their innovative research, including "First Award" winners, who each received a $6,000 prize.

    Category Winners (22):

    • Animal Sciences, sponsored by Jane Street 
      • Aakash Manaswi, 17, of Orlando, Florida
    • Behavioral and Social Sciences, sponsored by Jane Street 
      • Yaejoon Jung, 18, of Andover, Massachusetts
    • Biochemistry, sponsored by Regeneron 
      • Kaya Parikh, 17, of New York City, New York
    • Biomedical and Health Sciences, sponsored by Regeneron
      • Illaria Liedtke, 17, of Westchester, New York
    • Biomedical Engineering, sponsored by Regeneron 
      • Jamie Cheng, 17, of Cary, North Carolina
      • Natdanai Suksri, 17, of Mueang Chiang Mai, Thailand
      • Nattaphong Thaworn, 16, of Mueang Chiang Mai, Thailand
      • Poomjai Pongsriwat, 16, of Mueang Chiang Mai, Thailand
    • Cellular and Molecular Biology, sponsored by Regeneron
      • Evan Morris, 18, of Saint Paul, Minnesota
    • Chemistry, sponsored by Scripps Research
      • Benedikt Kienle, 19, of Lancaster, Pennsylvania
      • Lakshmi Agrawal, 18, of Bellevue, Washington
    • Computational Biology and Bioinformatics, sponsored by Regeneron
      • Eshan Vipuil, 17, of Melbourne, Florida
      • Mohammed Alasmari, 17, Jubail Industrial City, Saudi Arabia
    • Earth and Environmental Sciences, sponsored by Natural Resources Defense Council
      • Makaila Eagleton, 17, of Lincolndale, New York
      • Tina Jin, 15, of Andover, Massachusetts
    • Embedded Systems, sponsored by Jane Street
      • Filip Lajciak, 18, of Dubnica nad Vahom, Slovakia
    • Energy: Sustainable Materials and Design, sponsored by Siemens Energy
      • Janak Vasisht, 16, Arlington, Virginia
    • Engineering Technology: Statics and Dynamics, sponsored by Google.org
      • Ana Spiride, 16, of Plano, Texas
    • Environmental Engineering, sponsored by Jacobs
      • Bennett Huang, 17, of Mclean, Virginia
      • Jason Pan, 17, of Mclean, Virginia
      • Evan Budz, 15, of Burlington, Canada
    • Materials Science, sponsored by Howmet Aerospace Foundation
      • Arnav Kodavati, 17, of San Jose, California
      • Kevin Sun, 17, of Andover, Massachusetts
    • Mathematics, sponsored by Akamai Foundation
      • Nikola Veselinov, 17, of Sofia, Bulgaria
    • Microbiology, sponsored by Schattner Foundation
      • Audrey Cowen, 16, of Toronto, Canada
    • Physics and Astronomy, sponsored by Jane Street
      • Aryav Das, 17, of Indianapolis, Indiana
      • Saikrish Kolli, 17, of Lexington, Kentucky
      • Hikaru Kuribayashi, 17, of Sapporo, Japan
    • Plant Sciences, sponsored by Society for Science
      • Moitri Santra, 17, Oviedo, Florida
    • Robotics and Intelligent Machines, sponsored Zoox
      • Michael Hua, 16, Bloomfield Hills, Michigan
      • Qiyun Zheng, 16, of Shanghai, China
    • Software Design, sponsored by Microsoft
      • Sanjay Shreeyans Javangula, 17, of Bentonville, Arkansas
      • Soham Shekhar, 18, of Bentonville, Arkansas
      • Zack O' Leary, 15, of Clane, Ireland
    • Technology Enhances the Arts, sponsored by Midjourney
      • Anusha Arora, 15, of Bellevue, Washington
    • Translational Medical Science, sponsored by Regeneron
      • Lehansa Marambage, 17, Union City, New Jersey
      • Shivum Telang, 16, of Wexford, Pennsylvania



    Resources: 

    • Full list of all ISEF 2026 Grand Awards winners and Special Awards winners
    • View all the finalists' research projects here: https://isef.net/categories



    What is the Regeneron International Science and Engineering Fair (Regeneron ISEF)?

    Established in 1950, Regeneron ISEF, a program of Society for Science, is the world's largest global STEM competition for high school students. Through a global network of local, regional, and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Top winners earn the right to compete at Regeneron ISEF where more than 1,700 finalists are judged across 22 different categories, competing for more than $7 million in awards and scholarships.

    Who is sponsoring Regeneron ISEF?  

    In 2019, Regeneron became the title sponsor of ISEF to help reward and celebrate the best and brightest young minds globally and encourage them to pursue careers in STEM to positively impact the world. Regeneron is also the title sponsor of the Regeneron Science Talent Search (STS), a program of the Society for Science. Regeneron's support for these two premier programs will total more than $300 million from 2017 to 2036. Regeneron ISEF is supported by a community of additional sponsors, including entrepreneurs and organizations across a wide range of industries such as Adam R. Scripps Foundation, Akamai Foundation, Aramco, Arizona Science Center, Arizona State University, Burton Family Foundation, Caltech, Catalyzer Venture Partners, Central Arizona Project, Cesco Linguistic Services, Google.org, Gordon and Betty Moore Foundation, Howmet Aerospace Foundation, Insaco, Intel, Jacobs, Jane Street, Microsoft, Midjourney, Musical Instrument Museum, National Bank of Arizona, Natural Resources Defense Council, Pivotal Foundation, Schattner Foundation, Scripps Research, Siemens Energy, and Zoox.

    Learn more at https://www.societyforscience.org/isef/.

    What is Society for Science? 

    Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate, and inspire.  

    Learn more at www.societyforscience.org and follow us on Facebook, X, Instagram, and LinkedIn. 

    What is Regeneron? 

    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. 

    At Regeneron, science and responsible business practices go hand in hand. This conviction guides our 2030 responsibility goals, focused on delivering life-transforming medicines, expanding access to care, and supporting colleagues, communities and the ecosystems essential to human health. Through STEM-Fueled™ programming, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and numerous STEM initiatives, Regeneron supports science research pathways and ecosystems, helping cultivate the next generation of STEM innovators. In addition, Together for CHANGE™ is an initiative founded by Regeneron Genetics Center®, Meharry Medical College, and other biopharmaceutical partners to help address inequities in STEM careers and research. Regeneron has been repeatedly recognized for these efforts by the Dow Jones Best-in-Class Indices and the Civic 50 list of America's most community-minded companies.

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook, and X. 

    Media Contacts

    Tina Parisi Tuttle, Regeneron

    tina.parisituttle@regeneron.com

    Gayle Kansagor, Society for Science 

    703-489-1131, gkansagor@societyforscience.org



    Primary Logo

    Get the next $REGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    5/18/2026$700.00Buy → Neutral
    Citigroup
    5/18/2026$641.00Outperform → Market Perform
    Leerink Partners
    3/31/2026$875.00Overweight
    Piper Sandler
    3/6/2026$923.00Overweight
    Barclays
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    11/24/2025$798.00Buy
    Truist
    11/24/2025$255.00Buy
    HSBC Securities
    More analyst ratings

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

    Inmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity in vitro against multiple Ebola species, including Bundibugyo Maftivimab has been recommended to be studied as a monotherapy in the current outbreak TARRYTOWN, N.Y., May 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that maftivimab, the most potent neutralizing antibody

    5/28/26 4:00:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

    TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU). The MAA is supported by data from the pivotal CHORD clinical trial, in which 24 parti

    5/22/26 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations

    Regeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in.NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders saw the stock decline more than 10% when the market opened on May 18, 2026 after investors digested the weekend news that Regeneron's Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint versus Merck's Keytruda (pembrolizumab). Those who lost money on REGN are encouraged to submit their information to SueWallSt. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueW

    5/19/26 9:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    SEC Filings

    View All

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    5/8/26 4:09:13 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.

    10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    4/29/26 6:54:54 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    4/29/26 6:50:22 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Arthur F sold $70,524 worth of shares (100 units at $705.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.57% to 17,503 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    5/4/26 4:14:55 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ryan Arthur F

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    4/3/26 4:01:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Arthur F sold $78,550 worth of shares (100 units at $785.50), decreasing direct ownership by 0.56% to 17,703 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    3/3/26 4:01:53 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Regeneron Pharma downgraded by Citigroup with a new price target

    Citigroup downgraded Regeneron Pharma from Buy to Neutral and set a new price target of $700.00

    5/18/26 8:32:37 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Regeneron Pharma from Outperform to Market Perform and set a new price target of $641.00

    5/18/26 8:32:21 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on Regeneron Pharma with a new price target

    Piper Sandler resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $875.00

    3/31/26 8:17:54 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    View All

    Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

    TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,

    6/24/25 7:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

    TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

    1/30/24 7:00:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Financials

    Live finance-specific insights

    View All

    Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

    As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application submitted; cemdisiran could be the first siRNA to be approved for the treatment of gMG Regeneron to host virtual ‘Regeneron Roundtable: gMG & C5 Complement Program' investor event on Wednesday, April 22 at 8:30 a.m. ET TARRYTOWN, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis (gMG) w

    4/21/26 10:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

    TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detail

    3/25/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

    TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation

    1/2/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/13/24 5:12:22 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 6:19:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 9:49:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care